Privately-held French biotech TxCell and Ferring of Switzerland have signed a collaboration agreement potentially worth up to €76m plus royalties for TxCell's lead product Ovasave for the treatment of inflammatory bowel disease (IBD).
written on 18.03.2014
Ferring takes option on TxCell's IBD cell therapy
